At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Post-Mkt 03-17 16:08:14 EDT
2.27
+0.06
+2.71%
盘后2.27
+0.000.00%
16:04 EDT
High2.28Low2.24Vol23.65K
Open2.26D1 Closing2.21Amplitude1.81%
Mkt Cap30.60MTradable Cap19.61MTotal Shares13.48M
T/O53.53KT/O Rate0.27%Tradable Shares8.64M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support
Reuters  ·  03-11
Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support
Tempest Announces Partnership for Tpst-2003 in Preparation for Planned U.S. Registrational Study in 2026
THOMSON REUTERS  ·  03-11
Tempest Announces Partnership for Tpst-2003 in Preparation for Planned U.S. Registrational Study in 2026
Jakarta's Solution to Ease Burden on Bantargebang Landfill
Tempo  ·  03-11
Jakarta's Solution to Ease Burden on Bantargebang Landfill
Bantargebang Landfill Landslide Death Toll Rises to Five
Tempo  ·  03-10
Bantargebang Landfill Landslide Death Toll Rises to Five
Bantargebang Landfill Tragedy Shows Waste Management Failure, Minister Says
Tempo  ·  03-09
Bantargebang Landfill Tragedy Shows Waste Management Failure, Minister Says
3 People Killed in Bekasi's Bantargebang Landfill Landslide
Tempo  ·  03-08
3 People Killed in Bekasi's Bantargebang Landfill Landslide
Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy
Reuters  ·  02-25
Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy
Tempest Therapeutics Inc - Favorable Safety Profile With No Grade 3 or Higher Crs
THOMSON REUTERS  ·  02-25
Tempest Therapeutics Inc - Favorable Safety Profile With No Grade 3 or Higher Crs
Tempest Therapeutics: Co Also Exploring Potential Development of Tpst-2003 to Include Patients With Lbcl, Other Related Indications
THOMSON REUTERS  ·  02-25
Tempest Therapeutics: Co Also Exploring Potential Development of Tpst-2003 to Include Patients With Lbcl, Other Related Indications
Tempest Therapeutics Inc - to Initiate U.S. Registrational Study in 2026
THOMSON REUTERS  ·  02-25
Tempest Therapeutics Inc - to Initiate U.S. Registrational Study in 2026
Tempest Therapeutics Inc - 100% Complete Response Rate Among All Six Efficacy Evaluable Patients
THOMSON REUTERS  ·  02-25
Tempest Therapeutics Inc - 100% Complete Response Rate Among All Six Efficacy Evaluable Patients
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
GlobeNewswire  ·  02-25
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
Reuters  ·  02-11
BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs
Reuters  ·  02-11
BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs
Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies
Reuters  ·  02-11
Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies
Tempest Therapeutics Inc - Plans to Progress Additional Dual Targeting Tpst-3003 CAR-T Program
THOMSON REUTERS  ·  02-11
Tempest Therapeutics Inc - Plans to Progress Additional Dual Targeting Tpst-3003 CAR-T Program
Tempest Therapeutics Inc - Expects Phase 2B Initiation for Tpst-2003 by 2026 in China
THOMSON REUTERS  ·  02-11
Tempest Therapeutics Inc - Expects Phase 2B Initiation for Tpst-2003 by 2026 in China
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
THOMSON REUTERS  ·  02-11
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel
Reuters  ·  02-07
Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel
Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an
Reuters  ·  02-07
Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--